Xenoport (f/k/a XNPT)

[ghmm]

http://www.minyanville.com/businessmarkets/articles/acorda-therapeutics-ampyra-biogen-idec-fampyra/6/28/2011/id/35431?camp=syndication&medium=portals&from=yahoo

Cohen is thinking of other ways to boost sales short term -- specifically, with a drug acquisition. Acorda had $225 million in cash and marketable securities at the end of March. Cohen would like to use some of that cash to buy another company’s already approved drug to give his sales people another product to market to doctors.Cohen is thinking of other ways to boost sales short term -- specifically, with a drug acquisition. Acorda had $225 million in cash and marketable securities at the end of March. Cohen would like to use some of that cash to buy another company’s already approved drug to give his sales people another product to market to doctors.

Could be an interesting partner (for spasticity). Wonder if they would try to license before Phase 3 results.